BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Skepta and PUMA Launch Groundbreaking Collection 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Subaru and Toyota Collaborate on 3 New Electric SUVs, Citing ‘Huge Risk’ of Solo EVs 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
Lapstone & Hammer Expands ASICS 'Dip Dye' Series with Beverage-Inspired Colorways 
Green industry yes, conservation no: a budget for people, not for nature 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
NEW YORK, April 12, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of PTC Therapeutics, Inc. securities (NASDAQ:PTCT) from May 6, 2014 through February 23, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for PTC Therapeutics investors under the federal securities laws.
To join the PTC Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-843.html or call Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period issued materially false and misleading statements to investors and/or failed to disclose that: (1) PTC Therapeutics’ NDA for Translarna that it submitted to the FDA was not sufficiently complete to permit a substantive review of the application; (2), as such, the application would not be reviewed nor approved by the FDA; (3) the impending non-approval of the NDA would have a negative material impact on PTC Therapeutics’ operations and prospects; and (4) as a result, PTC Therapeutics’ financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-843.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
